In this study, we demonstrated the effects of CEP as a novel tumor-regional therapy for cutaneous melanoma basing on the finding that CEP could inhibit the growth of human primary cutaneous melanoma cells by altering the expression of cathepsin B, tumor suppressor genes, and autophagy-related proteins. This evidence concerns the gene CTSB and cutaneous melanoma.